TITLE

PHASE 3 TRIAL/STUDY OF ALDURAZYME FOR MPS I PROMISING

PUB. DATE
August 2002
SOURCE
Worldwide Biotech;Aug2002, Vol. 14 Issue 8, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
Reports on the results of the clinical trial of Aldurazyme, an investigational enzyme replacement therapy for patients with mucopolysaccharidosis I.
ACCESSION #
7095470

 

Related Articles

  • New drugs and dosage forms.  // American Journal of Health-System Pharmacy;4/1/2014, Vol. 71 Issue 7, p520 

    The article offers information on several drugs release in the U.S. in 2014 and their dosage forms including Elosulfase alfa injection from BioMarin Pharmaceutical, Indomethacin capsules from Iroko Pharmaceuticals and Metreleptin for injection from Bristol-Myers Squibb.

  • Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure.  // Orphanet Journal of Rare Diseases;2011, Vol. 6 Issue 1, p55 

    The article presents a European consensus procedure which showed the use of enzyme replacement therapy (ERT) and hematopoietic stem cell transplantation (HSCT) in the treatment of patient having mucopolysaccharidosis type I (MPS I). In this procedure a panel of specialists developed...

  • Attenuated mucopolysaccharidosis: are you missing this debilitating condition? Lampe, Christina // Rheumatology;Mar2012, Vol. 51 Issue 3, p401 

    The author offers clinical information on mucopolysaccharidosis (MPS), a rare condition often misdiagnosed because of the perception that this condition is a childhood disease. He explains that patients with attenuated or slow-progressing MPS will often fail to initially receive a correct...

  • OSTEOARTHROPATHY IN MUCOPOLYSACCHARIDOSIS TYPE II. NASCU, IOANA; GRIGORESCU-SIDO, PAULA; AL-KHZOUZ, CAMELIA; BUCERZAN, SIMONA; DENES, CARMENCITA; LAZEA, CECILIA // Clujul Medical;2013, Vol. 86 Issue 3, p270 

    Introduction. Mucopolysaccharidosis type II (MPS type II, Hunter syndrome) is a rare (~ 1/1500.000), X-linked inherited disorder (affects boys) due to deficiency of the lysosomal enzyme iduronate sulfatase (Xq.28). The complex clinical picture includes osteoarthropathy with a tendency to flexion...

  • Differential distribution of heparan sulfate glycoforms and elevated expression of heparan sulfate biosynthetic enzyme genes in the brain of mucopolysaccharidosis IIIB mice. McCarty, Douglas M.; DiRosario, Julianne; Gulaid, Kadra; Killedar, Smruti; Oosterhof, Arie; Van Kuppevelt, Toin H.; Martin, Paul T.; Haiyan Fu // Metabolic Brain Disease;Mar2011, Vol. 26 Issue 1, p9 

    The primary pathology in mucopolysaccharidosis (MPS) IIIB is lysosomal storage of heparan sulfate (HS) glycosaminoglycans, leading to complex neuropathology and dysfunction, for which the detailed mechanisms remain unclear. Using antibodies that recognize specific HS glycoforms, we demonstrate...

  • Structural study on mutant α- l-iduronidases: insight into mucopolysaccharidosis type I. Sugawara, Kanako; Saito, Seiji; Ohno, Kazuki; Okuyama, Torayuki; Sakuraba, Hitoshi // Journal of Human Genetics;May2008, Vol. 53 Issue 5, p467 

    To elucidate the basis of mucopolysaccharidosis type I (MPS I), we constructed structural models of mutant α- l-iduronidases (IDUAs) resulting from 33 amino acid substitutions that lead to MPS I (17 severe, eight intermediate, and eight attenuated). Then, we examined the structural changes in...

  • International Morquio A Registry: clinical manifestation and natural course of Morquio A disease.  // Current Medical Literature: Lysosomal Storage Disease;2007, Vol. 7 Issue 2, p48 

    The article discusses the clinical manifestation and natural course of Morquio A disease, an alternative name for mucopolysaccharidosis type IV (MPS IV), a form of skeletal dystrophy. The disease is caused by a deficiency in the enzyme originally called N-acetylgalactosamine-6-sulfatase, which...

  • Diagnosis and management of ophthalmological features in patients with mucopolysaccharidosis. Ferrari, Stefano; Ponzin, Diego; Ashworth, Jane L.; Fahnehjelm, Kristina Teär; Summers, C. Gail; Harmatz, Paul R.; Scarpa, Maurizio // British Journal of Ophthalmology;May2011, Vol. 95 Issue 5, p613 

    Ocular pathology is common in patients with mucopolysaccharidosis (MPS), a hereditary lysosomal storage disorder, where the eye as well as other tissues accumulate excessive amounts of glycosaminoglycans. Despite genetic and phenotypic heterogeneity within and between different types of MPS, the...

  • Expression of Active α-N-Acetylglucosaminidase/TAT Chimerae in Cultured Spodoptera frugiperda Cells. Bandsmer, Judith C.; Campbell, Tessa N.; Cheyne, Ian; Choy, Francis Y.M. // Protein & Peptide Letters;Apr2006, Vol. 13 Issue 4, p353 

    We examined the production and secretion of fusion constructs containing α-N-acetylglucosaminidase, the enzyme deficient in Sanfilippo B, and either wildtype TAT or modified TAT in cultured Spodoptera frugiperda cells. All constructs exhibited successful expression of active enzyme,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics